CAS: 53-03-2; Prednisone

上下游产品

CAS号125-10-0 醋酸泼尼松 | CAS号51192-49-5 17,21-dihydroxy... | CAS号52-21-1 醋酸泼尼松龙 | CAS号28449-43-6 (17Z)-11beta,21... | CAS号53-06-5 可的松 | CAS号50-04-4 醋酸可的松 | CAS号50-24-8 泼尼松龙 | CAS号125-10-0 醋酸泼尼松 | CAS号78261-67-3 (9S,10R,13S,14S...

醋酸泼尼松置于potassium Carbonate,溶剂黄146体系中,用 乙醇,水 作为反应溶剂,以68.5%的收率获得产物泼尼松
参考文献:一种泼尼松的制备方法
标题:一种泼尼松的制备方法
摘要:本发明公开了一种泼尼松的制备方法,属于药物的制备加工技术领域.该方法以醋酸氢化可的松为起始原料,经氧化,生物发酵脱氢,水解三个步骤,制备得到本发明所述的泼尼松.本发明所述泼尼松的制备方法通过改进传统工艺的不足,实现了目的产品纯度高,质量稳定性好,收率高,生产成本低,反应条件温和,避免了使用剧毒的氰试剂,本发明方法操作简便,适于工业化生产,具有广阔的市场前景.

专利信息

专利号:US-4440690-A
优先权日:1982-12-27
标题:Process for the synthesis of 6-bromo-17,21-dihydroxy 3,11,20-trioxo-1,4-pregnadienes 17,21-diesters
发明人：SHAPIRO ELLIOT L; FINKENOR LAWRENCE E
权利人:SCHERING CORP
摘要:Disclosed is an improved process for the synthesis of 6-bromo-17,21-dihydroxy-3,11,20-trioxo-1,4,-pregnadienes 17,21-diesters. In particular, this invention relates to the conversion of 17,21-dihydroxy-3,11,20-trioxo-1,4-pregnadienes 17,21-diesters to 6-borom-17,21-dihyroxy-3,11,20-trioxo-1,4-pregnadienes-17-21-diesters via bromination under ionic conditions, e.g. bromine in acetic acid.

专利号:US-2022265691-A1
优先权日:2019-07-12
标 题 :Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types
发明人：MAGNANI JOHN L; FOGLER WILLIAM E; THACKRAY HELEN M; FELDMAN ERIC J; STEWART DAVID
权利人:GLYCOMIMETICS INC
摘要:Cancer patients that express high levels of the E-selectin ligand (sialyl Lea/x) on their tumors have a poorer outcome. Interestingly, relapsed/refractory acute myeloid leukemia (AML) patients expressing high levels of sialyl Lex on their blasts show the greatest therapeutic response when treated with the E-selection inhibitor compound of Formula I. Transcriptome profiling of E-selectin ligand-forming glycosylation genes showed that ST3GAL4 and FUT7 were consistently expressed in the majority of cancers evaluated. Poor survival outcomes of FLT3-mutated AML patients that express high levels of ST3GAL4 and FUT7 implicated E-selectin in this disease state. These genes may be predictive biomarkers in AML patients. Methods of treatment of cancer comprising screening AML patients for expression of genes that contribute to the synthesis of the E-selectin ligand sialyl Lex, then treating those patients with an E-selection inhibitor, are disclosed.

专利号:US-4867914-A
优先权日:1982-02-26
标题:Pregnane derivatives and method of producing the same
发明人：BUNNO MASAYASU; HARADA HIDEMI; TSUJI MASAO; ICHIHARA YOSHIHIRO
权利人:KURARAY CO
摘要:There are provided 12-hydroxy- DELTA 4 or DELTA 1,4-pregnan-3-one-20-carbaldehyde and microbial method of producing the same. The compounds are novel and useful as starting materials for the synthesis of corticoids, typically prednisone, prednisolone and hydrocortisone, which have antiinflammatory activity.

专利号:US-4041055-A
优先权日:1975-11-17
标题:Process for the preparation of 17α-hydroxyprogesterones and corticoids from androstenes
发明人：SHEPHARD KENNETH PAUL; VAN RHEENEN VERLAN H
权利人:UPJOHN CO
摘要:This invention discloses a general process for the production of corticoids from androstenes. This invention provides an economically viable alternative synthesis of 17α-hydroxyprogesterones and the corticoids.

专利号:US-2019031650-A1
优先权日:2016-01-29
标 题 :Dna alkylation and cross-linking agents as compounds and payloads for targeted therapies
发明人：HERZON SETH; HEALY ALAN; CRAWFORD JASON; VIZCAINO MARIA; NIKOLAYEVSKIY HERMAN
权利人:UNIV YALE
摘要:The present invention is directed to compounds related to precolibactin pharmaceutical compositions based upon these compounds and methods of synthesis which are employed to provide intermediates and final compounds, which are principally alkylating agents and anticancer compounds. The chemical synthetic approach disclosed facilitates the synthesis of numerous precolibactin analogs which can be used in the treatment of cancer.

专利号:WO-9709067-A1
优先权日:1995-09-05
标 题 :Combination of 5-lipoxygenase and leukotriene synthesis inhibitors with glucocorticosteroids
发明人：BURCHARDT ELMAR-REINHOLD; MUELLER-PEDDINGHAUS REINER
权利人:BAYER AG; BURCHARDT ELMAR REINHOLD; MUELLER PEDDINGHAUS REINER
摘要:The combination is disclosed of 5-lipoxygenase inhibitors as direct action lipoxygenase inhibitors (LOI) or of leukotriene synthesis inhibitors (LSI) with glucocorticosteroids (GCS). This combination is suitable for treating and preventing various acute and chronic inflammatory processes, in particular of the respiratory tract, and may therefore be used as a medicament, in particular for treating asthma.